Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CD155 × Anti-Transferrin Receptor
- Development stage
- Preclinical
- Lead developer
- Tasrif Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-CD155 × Anti-Transferrin Receptor (TSRF-CNS) is a preclinical-stage brain-penetrating bispecific antibody being developed by Tasrif Pharmaceutical. It is designed to target the poliovirus receptor (CD155/PVR) for the treatment of central nervous system (CNS) malignancies, such as glioblastoma. The bispecific antibody is engineered with an anti-transferrin receptor (TfR) arm to facilitate receptor-mediated transcytosis across the blood-brain barrier (BBB), allowing the therapeutic anti-CD155 arm to accumulate within brain tumors and engage the target to modulate immune responses in the tumor microenvironment.
- Other names
- Anti-CD155 × Anti-TfRAnti-CD155 × Anti-TfR BispecificAnti-CD155 × Anti-Transferrin Receptor Bispecific
02
Targets
CD226 (DNAX accessory molecule 1)PVRTIGIT (T cell immunoreceptor with Ig and ITIM domains)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on Anti-CD155 × Anti-Transferrin Receptor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-CD155 × Anti-Transferrin Receptor.